MyLungCancerTeam

What mutations allow for targeted therapy in stage 4 lung adenocarcinoma, specifically KRAS and EGFR?

You're right on both counts! The "EKF" your nurse mentioned is likely EGFR (epidermal growth factor receptor), which is indeed a mutation that allows for targeted therapy. EGFR mutations are found in about 10-20% of NSCLC Show Full Answer

What mutations allow for targeted therapy in stage 4 lung adenocarcinoma, specifically KRAS and EGFR?

You're right on both counts! The "EKF" your nurse mentioned is likely EGFR (epidermal growth factor receptor), which is indeed a mutation that allows for targeted therapy. EGFR mutations are found in about 10-20% of NSCLC cases and have several FDA-approved targeted treatments available.

Good news about KRAS too - you're correct that targeted therapies now exist for certain KRAS mutations. For years, KRAS was considered untreatable, but that changed recently. If you have the specific KRAS G12C mutation (found in about 40% of KRAS cases), there are two FDA-approved targeted therapies: sotorasib (Lumakras) and adagrasib (Krazati).

Here's what to ask your oncologist Wednesday:

* Do I have the KRAS G12C mutation specifically?
* Do I have an EGFR mutation?
* Which targeted therapies am I eligible for based on my mutation profile?
* Are there clinical trials available for my specific mutations?

Having either EGFR or KRAS G12C mutations opens doors to targeted therapy options, so fingers crossed your testing reveals one of these treatable mutations!

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

How Does Targeted Therapy for Lung Cancer Work?

6 Lung Cancer Mutations and Treatments That Target Them